Indian metabolic disorder therapeutics market is estimated to grow at a CAGR of 8.5% during the forecast period. Significant awareness regarding health and the rising prevalence of metabolic disorders are contributing to the growth of the market. In India, the prevalence of diabetes in adults was 8.9% in 2019 and the total incidences of diabetes in adults was 77 million in 2019. Diabetes interrupts metabolism function, which increases the need for medications for the treatment of the condition. These medications include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia), and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is a thiazolidinediones group of medication which is intended for use as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR?)-responsive genes that participate in the regulation of fatty acid metabolism. 

Indian metabolic disorder therapeutics market is segmented based on type and disease. Based on type, the market is classified into drug therapy, gene therapy, cellular transplantation, enzyme replacement therapy, and others. In drug therapy, Metformin is a commonly used oral drug utilized to reduce blood glucose concentrations among patients with type-2 diabetes, primarily in patients who are obese and as well as those patients with normal renal function. Based on disease, the market is classified into obesity, diabetes, lysosomal storage disease, hypercholesterolemia, and others.

Some prominent players in the market include Lupin Ltd., Cipla Inc., AstraZeneca plc, and Biocon Ltd. Product launches and partnerships and collaborations have been reported significantly in the market. For instance, in November 2019, Lupin declared the launch of the US generic potassium chloride for the oral solution which is intended for the treatment and prevention of hypokalemia. This is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is inadequate. 

Research Methodology

The market study of the Indian metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Indian Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. Indian Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers

• Comprehensive research methodology of the Indian metabolic disorder therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Indian metabolic disorder therapeutics market.
• Insights about market determinants which are stimulating the Indian metabolic disorder therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.